Dexamethasone
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
- Dexamethasone
- Dexamethasone: From Adrenocortical Insufficiency and Inflammatory Conditions to Alopecia Areata
Dexamethasone: From Adrenocortical Insufficiency and Inflammatory Conditions to Alopecia Areata
One-Sentence Summary
Dexamethasone is a potent glucocorticoid originally used for conditions such as adrenocortical insufficiency, Crohn disease, acute lymphoblastic leukaemia and congenital adrenal hyperplasia. The TxGNN model predicts it may be effective for Alopecia Areata, with 0 registered clinical trials and 20 publications (including 1 randomised controlled trial and a network meta-analysis) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Adrenocortical insufficiency, Crohn disease and inflammatory bowel disease, acute lymphoblastic leukaemia, congenital adrenal hyperplasia, and others (from the knowledge graph; Singapore licence indication text is not available) |
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Based on general pharmacology, dexamethasone is a potent glucocorticoid with broad anti-inflammatory and immunosuppressive effects, including suppression of T-cell activation and pro-inflammatory cytokines.
Alopecia areata is a T-cell-mediated autoimmune disease in which cytotoxic CD8+ T cells attack the hair follicle, which normally enjoys immune privilege. Dampening this immune attack is the logical rationale for a glucocorticoid. Oral mini-pulse dexamethasone is an established off-label regimen, and the very high TxGNN score is consistent with the published clinical signal.
Note that the evidence rests on the literature alone, as no registered clinical trials were found.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36086930 | 2022 | RCT | Dermatologic Therapy | Open-label randomised study in 30 children with severe non-progressive alopecia areata comparing low-dose oral mini-pulse dexamethasone with DPCP contact sensitisation |
| 39042154 | 2024 | Systematic review / network meta-analysis | Archives of Dermatological Research | Compared systemic steroids, oral JAK inhibitors and contact immunotherapy in severe alopecia areata |
| 36461625 | 2023 | Review | Pediatric Dermatology | Reviewed dosing regimens and side effects of pulse corticosteroid therapy in children with alopecia areata |
| 35330017 | 2022 | Prospective cohort | Journal of Clinical Medicine | Real-world effectiveness and safety of oral mini-pulse corticosteroids, with factors associated with response |
| 36070222 | 2022 | Clinical study | Dermatologic Therapy | Multicentre study of oral mini-pulse dexamethasone in moderate to severe alopecia areata |
| 41872082 | 2026 | Clinical study (retrospective chart review) | European Journal of Dermatology | Pulse dexamethasone rescue added to baricitinib plus topical steroids in 19 patients with severe alopecia areata |
| 31579982 | 2019 | Prospective study | Dermatologic Therapy | 1-day versus 3-day intravenous dexamethasone pulses plus topical clobetasol in 73 children with severe disease |
| 26179196 | 2015 | Long-term follow-up study | Dermatologic Therapy | Oral dexamethasone pulses plus topical steroid in 65 children, median follow-up of 96 months |
| 10535249 | 1999 | Clinical study | Journal of Dermatology | Twice-weekly 5 mg oral dexamethasone pulse in 30 patients with extensive alopecia areata |
| 41243342 | 2025 | Case report/series | Journal of Dermatological Treatment | Durable remission with oral mini-pulse dexamethasone in patients not eligible for JAK inhibitors, with a focused review |
Singapore Market Information
The Singapore licence records compiled for this report do not include approved indication text.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN07155P | Dexamethasone Tablet 4 mg | Tablet | Not stated |
| SIN04238P | Dexamethasone Tablet 0.5 mg | Tablet | Not stated |
| SIN04295P | Dexamethasone Sodium Phosphate Injection USP | Injection | Not stated |
| SIN16866P | Dexamethasone Kalceks Solution for Injection/Infusion 4 mg/ml | Infusion, solution | Not stated |
| SIN14058P | Ozurdex Intravitreal Implant 0.7 mg | Implant | Not stated |
A total of 20 valid single-ingredient licences exist, covering tablets, elixir, injections, eye drops, ophthalmic ointments, an ocular insert and an oral paste.
Safety Considerations
- Contraindications (knowledge-graph associations, not label text): hypertension, epilepsy, hyperglycaemia, congestive heart failure, herpes simplex virus keratitis, measles, urea cycle disorders (carbamoyl phosphate synthetase I deficiency, citrullinemia, hyperargininemia), and pituitary hormone deficiency conditions (including hypopituitarism and growth hormone deficiency).
- Drug Interactions: 100 interactions were recorded. Major interactions include fentanyl and adalimumab. Moderate interactions include paclitaxel, abemaciclib, acalabrutinib, ibuprofen, ketorolac, nifedipine, acetazolamide, acarbose, isotretinoin and zidovudine.
- Related safety literature: Reviews of pulse corticosteroid therapy in children describe associated side effects; dosing and monitoring should follow these sources.
Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: One randomised controlled trial, a network meta-analysis and several cohort studies support oral mini-pulse dexamethasone in alopecia areata. However, no registered trials exist, the RCT is small and open-label, and the safety data are incomplete. The other nine predicted indications (alopecia mucinosa, telogen effluvium, folliculitis decalvans and others) have no meaningful supporting evidence and should remain on Hold.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (currently a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Larger randomised trials, ideally registered, comparing dexamethasone mini-pulse against JAK inhibitors or other standard care
- A monitoring plan for blood pressure, glucose and infection risk, particularly in children and patients with the contraindicated conditions listed above
- Confirmation of the route and formulation to be used (oral mini-pulse), since Singapore licence indication text is not available
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.